4.02
price down icon2.19%   -0.09
pre-market  Pre-market:  4.01   -0.010   -0.25%
loading
Xeris Biopharma Holdings Inc stock is traded at $4.02, with a volume of 1.65M. It is down -2.19% in the last 24 hours and down -30.81% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$4.11
Open:
$4.04
24h Volume:
1.65M
Relative Volume:
0.59
Market Cap:
$640.39M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-9.5714
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
-3.37%
1M Performance:
-30.81%
6M Performance:
+32.67%
1Y Performance:
+131.03%
1-Day Range:
Value
$3.95
$4.1698
1-Week Range:
Value
$3.95
$4.395
52-Week Range:
Value
$1.69
$6.07

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name
Name
Xeris Biopharma Holdings Inc
Name
Phone
844-445-5704
Name
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Name
Employee
394
Name
Twitter
@XerisPharma
Name
Next Earnings Date
2024-12-08
Name
Latest SEC Filings
Name
XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XERS
Xeris Biopharma Holdings Inc
4.02 640.39M 181.41M -59.56M -38.83M -0.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-11-24 Downgrade Piper Sandler Overweight → Neutral
Mar-28-24 Initiated Oppenheimer Outperform
Aug-28-23 Initiated Craig Hallum Buy
Oct-21-22 Initiated Jefferies Buy
Apr-28-22 Initiated Craig Hallum Buy
Nov-17-21 Initiated SVB Leerink Outperform
Oct-29-21 Initiated H.C. Wainwright Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Feb-18-20 Initiated Piper Sandler Overweight
Jul-16-18 Initiated Jefferies Buy
Jul-16-18 Initiated Leerink Partners Outperform
Jul-16-18 Initiated RBC Capital Mkts Outperform
View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

pulisher
Apr 21, 2025

JPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Apr 21, 2025
pulisher
Apr 21, 2025

Alliancebernstein L.P. Reduces Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Apr 21, 2025
pulisher
Apr 17, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short Interest - Defense World

Apr 17, 2025
pulisher
Apr 15, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Raymond James Financial Inc. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Wellington Management Group LLP Sells 6,532 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Purchased by Prudential Financial Inc. - Defense World

Apr 12, 2025
pulisher
Mar 31, 2025

AIGH Capital Management LLC Purchases 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Auto-Injectors Market Growth in Future Scope 2025-2032 | Sanofi - openPR

Mar 31, 2025
pulisher
Mar 28, 2025

Xeris Pharmaceuticals Announces Board Changes with New Appointment - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Xeris Biopharma reshuffles board, appoints new director By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Xeris Announces Changes To Its Board Of Directors - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Xeris Biopharma reshuffles board, appoints new director - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Xeris Announces Changes to Its Board of Directors - Business Wire

Mar 28, 2025
pulisher
Mar 27, 2025

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? - Insider Monkey

Mar 27, 2025
pulisher
Mar 25, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 25, 2025
pulisher
Mar 23, 2025

Don't Ignore The Insider Selling In Xeris Biopharma Holdings - simplywall.st

Mar 23, 2025
pulisher
Mar 23, 2025

Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% – Here’s Why - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock - Investing.com India

Mar 22, 2025
pulisher
Mar 21, 2025

Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Xeris Pharmaceuticals stock hits 52-week high at $5.54 - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Xeris Pharmaceuticals stock hits 52-week high at $5.54 By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 20, 2025

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High – Time to Buy? - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game - Insider Monkey

Mar 19, 2025
pulisher
Mar 19, 2025

Xeris enters a whole new market for one of its main pharma offerings - Crain's Chicago Business

Mar 19, 2025
pulisher
Mar 19, 2025

Is XERS Stock a Good Buy in 2025? Key Insights for Investors - Stocks Telegraph

Mar 19, 2025
pulisher
Mar 18, 2025

12 Best Stocks to Invest in for a Stock Market Game - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent - Investing.com Australia

Mar 18, 2025
pulisher
Mar 17, 2025

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid - BioSpace

Mar 17, 2025
pulisher
Mar 17, 2025

Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use -March 17, 2025 at 08:33 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 16, 2025

Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator (NASDAQ:XERS) - Seeking Alpha

Mar 16, 2025
pulisher
Mar 16, 2025

Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34% - Simply Wall St

Mar 16, 2025
pulisher
Mar 16, 2025

Xeris BiopharmaPossibly the best Pharma Stock - MSN

Mar 16, 2025
pulisher
Mar 13, 2025

Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $5.92 - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Will Xeris Biopharma's Financial Transformation Reach New Heights In 2025? - RTTNews

Mar 11, 2025
pulisher
Mar 11, 2025

Xeris Biopharma (XERS) Expects to Ride the Wave of 30% Revenue Growth in 2025 - Markets Insider

Mar 11, 2025
pulisher
Mar 10, 2025

What Are Expectations For Xeris Biopharma Holdings Inc (NASDAQ: XERS) In The Short Term? - Stocks Register

Mar 10, 2025
pulisher
Mar 10, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 10, 2025
pulisher
Mar 10, 2025

Analysts Issue Forecasts for Xeris Biopharma Q1 Earnings - Defense World

Mar 10, 2025

Xeris Biopharma Holdings Inc Stock (XERS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Cap:     |  Volume (24h):